These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31375039)

  • 1. Indian consensus on the management of CRE infection in critically ill patients (ICONIC) - India.
    Soman R; Veeraraghavan B; Hegde A; Jiandani P; Mehta Y; Nagavekar V; Rodrigues C; Singh RK; Swaminathan S; Todi S; Varma S; Patil S; Barkate H
    Expert Rev Anti Infect Ther; 2019 Aug; 17(8):647-660. PubMed ID: 31375039
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.
    Neuner EA; Gallagher JC
    Virulence; 2017 May; 8(4):440-452. PubMed ID: 27589330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
    Zavascki AP; Klee BO; Bulitta JB
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):519-526. PubMed ID: 28375030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections.
    Trecarichi EM; Tumbarello M
    Virulence; 2017 May; 8(4):470-484. PubMed ID: 28276996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Triple-Disk Enrichment Method for Carbapenem-Resistant Enterobacteriaceae (CRE) Screening.
    Darling LA; Evans AM; Stellrecht KA; Nattanmai SM; Montero CI
    J Clin Microbiol; 2017 Dec; 55(12):3557-3559. PubMed ID: 28931562
    [No Abstract]   [Full Text] [Related]  

  • 6. Methods and issues in studies of CRE.
    Evans SR; Harris AD
    Virulence; 2017 May; 8(4):453-459. PubMed ID: 27470534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections.
    Pascale R; Giannella M; Bartoletti M; Viale P; Pea F
    Expert Rev Anti Infect Ther; 2019 Oct; 17(10):819-827. PubMed ID: 31559876
    [No Abstract]   [Full Text] [Related]  

  • 8. Precision medicine for the diagnosis and treatment of carbapenem-resistant Enterobacterales: time to think from a different perspective.
    Reyes S; Nicolau DP
    Expert Rev Anti Infect Ther; 2020 Aug; 18(8):721-740. PubMed ID: 32368940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
    Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germs of thrones - spontaneous decolonization of Carbapenem-Resistant Enterobacteriaceae (CRE) and Vancomycin-Resistant Enterococci (VRE) in Western Europe: is this myth or reality?
    Davido B; Moussiegt A; Dinh A; Bouchand F; Matt M; Senard O; Deconinck L; Espinasse F; Lawrence C; Fortineau N; Saleh-Mghir A; Caballero S; Escaut L; Salomon J
    Antimicrob Resist Infect Control; 2018; 7():100. PubMed ID: 30123500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
    Pang F; Jia XQ; Zhao QG; Zhang Y
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenem-resistant enterobacteriaceae screening: A core infection control measure for critical care unit in India?
    Ramanathan YV; Venkatasubramanian R; Nambi PS; Ramabathiran M; Venkataraman R; Thirunarayan MA; Samundeeswari P; Ramakrishnan N
    Indian J Med Microbiol; 2018; 36(4):572-576. PubMed ID: 30880709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for carriage of carbapenem-resistant Enterobacteriaceae in settings of high endemicity: a position paper from an Italian working group on CRE infections.
    Ambretti S; Bassetti M; Clerici P; Petrosillo N; Tumietto F; Viale P; Rossolini GM
    Antimicrob Resist Infect Control; 2019; 8():136. PubMed ID: 31423299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae.
    Watkins RR; Deresinski S
    Expert Rev Anti Infect Ther; 2017 Oct; 15(10):893-895. PubMed ID: 28914107
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae.
    Freire MP; de Oliveira Garcia D; Cury AP; Francisco GR; Dos Santos NF; Spadão F; Bueno MFC; Camargo CH; de Paula FJ; Rossi F; Nahas WC; David-Neto E; Pierrotti LC
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):755-765. PubMed ID: 30680569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study.
    Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL
    Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of intestinal carriage of carbapenem-resistant Enterobacteriaceae among inpatients at two Iranian university hospitals: first report of co-production of bla
    Solgi H; Badmasti F; Aminzadeh Z; Giske CG; Pourahmad M; Vaziri F; Havaei SA; Shahcheraghi F
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2127-2135. PubMed ID: 28639165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The epidemiology and risk factor of carbapenem-resistant enterobacteriaceae colonization and infections: Case control study in a single institute in Japan.
    Asai N; Sakanashi D; Suematsu H; Kato H; Hagihara M; Nishiyama N; Koizumi Y; Yamagishi Y; Mikamo H
    J Infect Chemother; 2018 Jul; 24(7):505-509. PubMed ID: 29548627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fast and expensive (PCR) or cheap and slow (culture)? A mathematical modelling study to explore screening for carbapenem resistance in UK hospitals.
    Knight GM; Dyakova E; Mookerjee S; Davies F; Brannigan ET; Otter JA; Holmes AH
    BMC Med; 2018 Aug; 16(1):141. PubMed ID: 30111322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.